SAM
Sectoral Asset Management Portfolio holdings
AUM
$151M
1-Year Return
14.02%
This Quarter Return
+3.76%
1 Year Return
+14.02%
3 Year Return
+79.35%
5 Year Return
+153.48%
10 Year Return
+511.68%
AUM
$151M
AUM Growth
+$23M
(+18%)
Cap. Flow
+$26.9M
Cap. Flow
% of AUM
17.79%
Top 10 Holdings %
Top 10 Hldgs %
42.26%
Holding
109
New
25
Increased
23
Reduced
25
Closed
15
Top Buys
| 1 |
MBX
MBX Biosciences, Inc. Common Stock
MBX
|
$2.19M |
| 2 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$2.16M |
| 3 |
Replimune Group
REPL
|
$2.15M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$2.15M |
| 5 |
Solid Biosciences
SLDB
|
$2.05M |
Top Sells
| 1 |
Medtronic
MDT
|
$2.14M |
| 2 |
Gilead Sciences
GILD
|
$1.37M |
| 3 |
Tenet Healthcare
THC
|
$1.21M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$1.12M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$994K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
LENZ
1
LENZ Therapeutics
LENZ
$1.14B
| $28.6M | 18.91% |
977,245
| – | – |
|
2
Eli Lilly
LLY
$666B
| $7M | 4.62% |
8,976
-440
| -5% | -$343K |
|
3
UnitedHealth
UNH
$281B
| $5.22M | 3.45% |
16,745
+3,850
| +30% | +$1.2M |
|
4
Mineralys Therapeutics
MLYS
$2.2B
| $5.17M | 3.42% |
382,415
+11,902
| +3% | +$161K |
|
|
CTNM
5
Contineum Therapeutics
CTNM
$308M
| $3.18M | 2.1% |
800,787
| – | – |
|
6
Amgen
AMGN
$151B
| $3.15M | 2.08% |
11,270
+885
| +9% | +$247K |
|
7
Vertex Pharmaceuticals
VRTX
$102B
| $3.09M | 2.04% |
6,945
+2,220
| +47% | +$988K |
|
8
Johnson & Johnson
JNJ
$431B
| $2.95M | 1.95% |
19,300
-2,500
| -11% | -$382K |
|
9
Intuitive Surgical
ISRG
$163B
| $2.85M | 1.88% |
5,250
| – | – |
|
10
AbbVie
ABBV
$376B
| $2.75M | 1.81% |
14,800
| – | – |
|
|
11
Oric Pharmaceuticals
ORIC
$1.05B
| $2.35M | 1.55% |
231,485
+211,485
| +1,057% | +$2.15M |
|
12
Boston Scientific
BSX
$159B
| $2.27M | 1.5% |
21,126
-3,100
| -13% | -$333K |
|
13
argenx
ARGX
$44.9B
| $2.25M | 1.49% |
4,085
+982
| +32% | +$541K |
|
|
MBX
14
MBX Biosciences, Inc. Common Stock
MBX
$434M
| $2.19M | 1.45% |
+191,825
| New | +$2.19M |
|
|
15
Gilead Sciences
GILD
$140B
| $2.18M | 1.44% |
19,690
-12,330
| -39% | -$1.37M |
|
|
PVLA
16
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $2.16M | 1.42% |
+95,615
| New | +$2.16M |
|
|
17
Replimune Group
REPL
$454M
| $2.15M | 1.42% |
+231,650
| New | +$2.15M |
|
18
Arcus Biosciences
RCUS
$1.23B
| $2.09M | 1.38% |
257,270
+230,400
| +857% | +$1.88M |
|
19
Danaher
DHR
$143B
| $2.09M | 1.38% |
10,575
| – | – |
|
20
Abbott
ABT
$231B
| $2.07M | 1.36% |
15,198
-3,500
| -19% | -$476K |
|
|
21
Solid Biosciences
SLDB
$433M
| $2.05M | 1.36% |
+421,580
| New | +$2.05M |
|
|
RAPP
22
Rapport Therapeutics
RAPP
$560M
| $2.05M | 1.35% |
+179,860
| New | +$2.05M |
|
|
ZBIO
23
Zenas BioPharma, Inc. Common Stock
ZBIO
$715M
| $2.04M | 1.35% |
+210,625
| New | +$2.04M |
|
24
Ventyx Biosciences
VTYX
$185M
| $1.99M | 1.32% |
+931,620
| New | +$1.99M |
|
|
TECX
25
Tectonic Therapeutic, Inc. Common Stock
TECX
$323M
| $1.97M | 1.3% |
+98,970
| New | +$1.97M |
|